Isolated regional limb perfusion in the treatment of patients with melanoma of the skin
Abstract
It was performed an analysis of published data on possible methods of isolated regional perfusion (IRP) in the treatment of locally advanced extremity melanoma. It is shown that the method is becoming more common as superior to other methods in the treatment of tumors of this embodiment. It was found that when using IRP average five-year survival without signs of the disease is 39%, while in patients underwent IRP was unresectable tumor with a poor prognosis. In regard to safety performance it demonstrated that IRP is rarely accompanied by severe manifestations of local or systemic toxicity. These data confirm the safety and the possibility of using IRP method in a clinical setting. The study of patients after IRP quality of life showed an increase in its level after treatment by this method. There are reports on the efficacy of the method in combination with surgical treatment of the tumor. However, to date there is no evidence that adjuvant IRP extends the life of patients with melanoma, indicating a need for further research possibilities of this method.
About the Author
N. S. Petrochenko
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
References
1. Alexander H.R., Fraker D.L., Bartlett D.L. et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoin isolated limb perfusion using modern treatment parameters. J. Clin. Oncol. 2010, v. 28, p. 114-118.
2. Balch C.M., Buzaid A.C., Soong S.J. et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, v. 19, p. 3635-3648.
3. Beasley G.M., Caudle A., Petersen R.P. et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J. Am. Coll Surg. 2009, v. 208, p. 706-715.
4. Chapman P.B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, v. 364, p. 2507-2516.
5. Coventry B.J., Ashdown M.L. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag. Res. 2012, v. 4, p. 137-149.
6. Coventry B.J., Kroon H.M., Giles M.H. et al. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. J. Surg. Oncol. 2014, v. 109 (8), p. 780-785.
7. Di Filippo F., Giacomini P., Rossi C.R. et al. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNF-based isolated limb perfusion. In Vivo. 2009, v. 23, p. 347-352.
8. Dong X.D., Tyler D., Jonson J.L. et al. Analysis of prognosis and disease progression alter local recurrence of melanoma. Cancer. 2000, v. 88, p. 1063-1071.
9. Duprat Neto J.P., MauroA.C., MolinaA.S. et al. Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity. ANZ J. Surg. September 24, 2012. [Epub ahead of print.]
10. Eggermont A.M., Kirkwood J.M. Re-evaluating of the role of dacarbazin in metastatic melanoma: What have we learned in 30 years? Eur. J. Cancer. 2004, v. 40, p. 1825-1836.
11. Foote M.C., Burmeister B.H., Thomas J., Mark Smithers B. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res. 2010, v. 20, p. 48-51.
12. Giles M.H., Coventry B.J. Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Manag. Res. 2013, v. 5, p. 243-249.
13. Gogas H.J., Kirkwood J.M., SondakV.K. Chemotherapy for metastatic melanoma: Time for a change? Cancer. 2007, v. 109, p. 455-464.
14. Green D.S., Bodman-SmithM.D., DalgleishA.G. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br. J. Dermatol. 2007, v. 156, p. 337-345.
15. Hoekstra H.J., Veerman K., van Ginkel R.J. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion? J. Surg. Oncol. 2014, v. 109 (4), p. 338-347.
16. Hong A., Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J. 2012, v. 18, p. 203-207.
17. Kroon H.M., Moncrieff M., Kam P.C., Thompson J.F. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann. Surg. Oncol. 2008, v. 15, p. 3003-3013.
18. Kroon H.M., Thompson J.F. Isolated limb infusion: a review. J. Surg. Oncol. 2009, v. 100, p. 169-177.
19. Li Y., McClay E.F. Systemic chemotherapy for the treatment of metastatic melanoma. Semin. Oncol. 2002, v. 29, p. 413-426.
20. Moreno-Ramirez D., de la Cruz-Merino L., Ferrandiz L. et al. Study an treatment of locally advanced melanoma. Actas. Dermosifiliogr. 2009, v. 100, p. 767-779.
21. Noorda E.M., van Kreij R.H.J., Vrouenraets B.C. et al. The healthrelated quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur. J. Surg. Oncol. 2007, v. 33, p. 776-782.
22. Olofsson Bagge R., Mattsson J., Hafstrom L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomized trial. Int. J. Hyperthermia. 2014, v. 30 (5), p. 295-298. doi: 10.3109/02656736.2014.931601.
23. Radny P., Carola U.M., Bauer J. et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br. J. Cancer. 2003, v. 89, p. 1620-1626.
24. Rossi C.R., Foletto M., Mocellin S. et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann. Surg. Oncol. 2004, v. 11, p. 173-177.
25. Sause W.T., Cooper J.S., Rush S. et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int. J. Radiat. Oncol. Biol. Phys. 1991, v. 20, p. 429-432.
26. Sosman J.A., Kim K.B., Schuchter L. et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, v. 366, p. 707-714.
27. Stevens G., McKay M.J. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol. 2006, v. 7, p. 575-583.
28. Testori A., Faries M.B., Thompson J.F. et al. Local and intralesional therapy of in-transit melanoma metastases. J. Surg. Oncol. 2011, v. 104, p. 391-396.
29. Thompson J.F., Hersey P., Wachter E. Chemoablation of metastatic melanoma using intralesional rose bengal. Melanoma Res. 2008, v. 18, p. 405-411.
30. Vrouenraets B.C., Hart G.A.M., Eggermont A.M.M. et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J. Am. Coll. Surg. 1999, v. 188, p. 522-530.
31. Wolf I.H., Smolle J., Binder B. et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch. Dermatol. 2003, v. 139, p. 273-276.
Review
For citations:
Petrochenko N.S. Isolated regional limb perfusion in the treatment of patients with melanoma of the skin. Bone and soft tissue sarcomas, tumors of the skin. 2015;(2):12-16. (In Russ.)
Views:
90
Email this article 
